SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-083443
Filing Date
2022-03-24
Accepted
2022-03-24 09:08:19
Documents
17
Period of Report
2022-03-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d337089d8k.htm   iXBRL 8-K 70400
2 EX-2.1 d337089dex21.htm EX-2.1 1908924
3 EX-2.2 d337089dex22.htm EX-2.2 368784
4 EX-2.3 d337089dex23.htm EX-2.3 40623
5 EX-2.4 d337089dex24.htm EX-2.4 79554
6 EX-10.1 d337089dex101.htm EX-10.1 143490
  Complete submission text file 0001193125-22-083443.txt   3355391

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA lgnd-20220323.xsd EX-101.SCH 2854
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE lgnd-20220323_lab.xml EX-101.LAB 17995
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lgnd-20220323_pre.xml EX-101.PRE 11260
11 EXTRACTED XBRL INSTANCE DOCUMENT d337089d8k_htm.xml XML 3404
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 22764853
SIC: 2834 Pharmaceutical Preparations